{"id":523952,"date":"2021-08-05T07:33:34","date_gmt":"2021-08-05T11:33:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/"},"modified":"2021-08-05T07:33:34","modified_gmt":"2021-08-05T11:33:34","slug":"transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/","title":{"rendered":"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138<\/b><\/p>\n<p class=\"bwalignc\"><strong><span style=\"font-weight:normal\">&#8212; TTX-MC138 targets MicroRNA10b for treatment of metastatic disease; TransCode on track to submit exploratory investigational new drug (eIND) application in Q1 2022 &#8212;<\/span><\/strong><\/p>\n<p>BOSTON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nTransCode Therapeutics, Inc. (Nasdaq: RNAZ), a platform company solving the challenge of RNA delivery in oncology, today announced that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support the clinical evaluation of TTX-MC138, TransCode\u2019s lead therapeutic candidate for the treatment of metastatic solid tumors. The award totals $2.3 million expected over three years.\n<\/p>\n<p>\n\u201cWe are honored that the NIH recognizes and supports our mission to overcome the obstacles of RNA delivery in oncology,\u201d said Michael Dudley, President and Chief Executive Officer of TransCode. \u201cWe believe our TTX delivery platform offers tremendous potential across a range of indications. Specifically, this SBIR grant will help fund our planned first-in-human study of our lead candidate, TTX-MC138, in patients with metastatic breast cancer. We look forward to submitting an eIND application in the first quarter of next year. This trial is designed to evaluate and demonstrate proof-of-concept for the mechanism of action for our novel delivery platform, potentially enabling TransCode to pursue a diverse pipeline of TTX-based therapeutics.\u201d\n<\/p>\n<p>\nTransCode\u2019s proprietary TTX platform leverages an iron oxide nanoparticle as a novel, image-guided system to safely and efficiently deliver oligonucleotides to their intended RNA target. TTX-MC138 targets MicoRNA-10b, believed to drive metastatic disease. The therapeutic has been validated preclinically in multiple indications and has been shown to induce durable regressions of metastatic disease in murine models of disseminated breast cancer.\n<\/p>\n<p><b>About TransCode Therapeutics<\/b><\/p>\n<p>\nTransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company\u2019s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company\u2019s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p><i>This release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the SBIR grant, including the expected timing and receipt of the funds thereunder, and statements concerning the planned first-in-human study of TTX-MC138, including the timing of the planned eIND for this study and the outcome of this study, including whether this study will demonstrate proof-of-concept, and statements concerning TransCode\u2019s development programs and TTX technology platform generally. Any forward-looking statements in this press release are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risk associated with drug discovery and development; the risk that the results of our planned clinical trials will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode s planned regulatory submissions; risks associated with TransCode\u2019s planned clinical trials for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode\u2019s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with TransCode\u2019s financial condition and its need to obtain additional funding to support its business activities, including TransCode\u2019s ability to continue as a going concern; risks associated with TransCode\u2019s dependence on third parties; and risks associated with the COVID-19 coronavirus. For a discussion of other risks and uncertainties, and other important factors, any of which could cause TransCode\u2019s actual results to differ from those contained in the forward-looking statements, see the section entitled \u201cRisk Factors\u201d in TransCode\u2019s Final Prospectus for its initial public offering filed with the Securities and Exchange Commission on July 9. 2021, as well as discussions of potential risks, uncertainties and other important factors in TransCode\u2019s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Allena undertakes no duty to update this information unless required by law.<\/i><\/p>\n<p>\nThe names of other companies and products mentioned herein may be trademarks of their respective owners.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210805005399\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210805005399\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Josh Rappaport<br \/>\n<br \/>Stern Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:josh.rappaport@sternir.com\">josh.rappaport@sternir.com<\/a><\/p>\n<p><b>Company Contact:<br \/>\n<\/b><br \/>Tom Fitzgerald, CFO<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:tom.fitzgerald@transcodetherapeutics.com\">tom.fitzgerald@transcodetherapeutics.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210805005399\/en\/896793\/3\/TransCode_Therapeutics_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 &#8212; TTX-MC138 targets MicroRNA10b for treatment of metastatic disease; TransCode on track to submit exploratory investigational new drug (eIND) application in Q1 2022 &#8212; BOSTON&#8211;(BUSINESS WIRE)&#8211; TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a platform company solving the challenge of RNA delivery in oncology, today announced that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support the clinical evaluation of TTX-MC138, TransCode\u2019s lead therapeutic candidate for the treatment of metastatic solid tumors. The award totals $2.3 million expected over three years. \u201cWe are honored that the NIH recognizes and supports our mission to overcome the obstacles of RNA &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-523952","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 &#8212; TTX-MC138 targets MicroRNA10b for treatment of metastatic disease; TransCode on track to submit exploratory investigational new drug (eIND) application in Q1 2022 &#8212; BOSTON&#8211;(BUSINESS WIRE)&#8211; TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a platform company solving the challenge of RNA delivery in oncology, today announced that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support the clinical evaluation of TTX-MC138, TransCode\u2019s lead therapeutic candidate for the treatment of metastatic solid tumors. The award totals $2.3 million expected over three years. \u201cWe are honored that the NIH recognizes and supports our mission to overcome the obstacles of RNA &hellip; Continue reading &quot;TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-05T11:33:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138\",\"datePublished\":\"2021-08-05T11:33:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/\"},\"wordCount\":873,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210805005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/\",\"name\":\"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210805005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-08-05T11:33:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210805005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210805005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/","og_locale":"en_US","og_type":"article","og_title":"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Market Newsdesk","og_description":"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 &#8212; TTX-MC138 targets MicroRNA10b for treatment of metastatic disease; TransCode on track to submit exploratory investigational new drug (eIND) application in Q1 2022 &#8212; BOSTON&#8211;(BUSINESS WIRE)&#8211; TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a platform company solving the challenge of RNA delivery in oncology, today announced that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support the clinical evaluation of TTX-MC138, TransCode\u2019s lead therapeutic candidate for the treatment of metastatic solid tumors. The award totals $2.3 million expected over three years. \u201cWe are honored that the NIH recognizes and supports our mission to overcome the obstacles of RNA &hellip; Continue reading \"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-05T11:33:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138","datePublished":"2021-08-05T11:33:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/"},"wordCount":873,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/","name":"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-08-05T11:33:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-awarded-funding-from-national-institutes-of-health-nih-to-support-clinical-evaluation-of-ttx-mc138\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/523952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=523952"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/523952\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=523952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=523952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=523952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}